Current Review of Monoclonal Antibody Therapeutics in Small Animal Medicine
Animals · 07.02.2025 · 15 (4) · 472
DOI: 10.3390/ani15040472 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Animals, online erschienen am 07.02.2025. Verfasst von Jianzhong Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Shanxi Key Laboratory for Modernization of TCVM, College of Veterinary Medicine, Shanxi Agricultural University, Taigu 030801, China. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Central Funds Guiding the Local Science and Technology Development in Shanxi Province, Project of Scientific Research for Excellent Doctors, Shanxi Province, China, Research Fund (Clinical Diagnosis And Treatment Of Pet) For Young College Teachers in Ruipeng Commonweal Foundation.
Abstract (Originalsprache)
Monoclonal antibody therapy has been a cornerstone of human healthcare for nearly four decades, effectively treating a wide range of diseases including cancers, autoimmune disorders, and inflammatory conditions. However, its application in veterinary medicine is a relatively recent development, offering a promising therapeutic approach for managing chronic diseases in small animals. Dogs and cats, like humans, suffer from chronic conditions such as cancer, arthritis, allergies, and chronic pain, which mAb therapy could potentially address. This review aims to explore the therapeutic potential of mAb therapy in small animal medicine, focusing on currently authorized products, including their mechanisms of action, clinical efficacy, and safety concerns. A comprehensive review of the literature was conducted to evaluate the use of mAbs in veterinary medicine, specifically in the treatment of chronic disorders. While mAb therapy has shown significant benefits in human healthcare, challenges remain in its application to veterinary practice, including safety concerns and the limited availability of approved products. Despite these challenges, mAb therapy holds great promise for improving the management of chronic diseases in animals, with future research and development potentially expanding its clinical use.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Shanxi Key Laboratory for Modernization of TCVM, College of Veterinary Medicine, Shanxi Agricultural University, Taigu 030801, China.
- Department of Veterinary Clinical Science, College of Veterinary Medicine, China Agricultural University, Beijing 100107, China.
- Department of Pharmacology, Faculty of Veterinary Medicine, Mansoura University, Mansoura 35516, Egypt.
- Institute of Qinhai-Tibetan Plateau, College of Animal Husbandry and Veterinary Medicine, Southwest Minzu University, Chengdu 610041, China.
- Department of Biomedical Sciences, College of Veterinary Medicine, Iowa State University, Ames, IA 50011, USA.
ORCID-Profile: Jianzhong Wang, Sara T Elazab
Förderung
- Central Funds Guiding the Local Science and Technology Development in Shanxi Province
- Project of Scientific Research for Excellent Doctors, Shanxi Province, China
- Research Fund (Clinical Diagnosis And Treatment Of Pet) For Young College Teachers in Ruipeng Commonweal Foundation
- Natural Scence Foundation of Sichuan Province
Zitieren
APA
Wang, J., Zhou, X., Elazab, S. T., Huang, J., & Hsu, W. H. (2025). Current Review of Monoclonal Antibody Therapeutics in Small Animal Medicine. Animals, 15(4), 472. https://doi.org/10.3390/ani15040472
Vancouver
Wang J, Zhou X, Elazab ST, Huang J, Hsu WH. Current Review of Monoclonal Antibody Therapeutics in Small Animal Medicine. Animals. 2025;15(4):472. doi:10.3390/ani15040472
BibTeX
@article{Wang2025,
author = {Wang, Jianzhong and Zhou, Xueying and Elazab, Sara T and Huang, Jian and Hsu, Walter H},
title = {Current Review of Monoclonal Antibody Therapeutics in Small Animal Medicine},
journal = {Animals},
year = {2025},
volume = {15},
number = {4},
pages = {472},
doi = {10.3390/ani15040472}
}
EUVIMED